Application No.: 09/357,704 Filed: July 20, 1999

Page 11 of 11

REMARKS

Interview Summary

Applicant thanks the Examiner for the telephone calls of September 18 and 21, during

which the instant application and co-owned U.S. Patent No. 7,514,078 were discussed.

In the Claims

Applicant amended claims 69 and 124-127, and cancelled claims 130, 191, and 194, to

remove the recitation of a monoclonal antibody produced by a hybridoma with an ATCC accession number HB-12109 from the claims. The amended claims are supported by the

originally filed specification and claims, and do not introduce any new matter.

Applicant made these amendments solely to expedite allowance and reserves all rights to

pursue the subject matter of this application in claims of the same, broader, or narrower scope,

including any prior version or listing of the claims, in the future.

Terminal Disclaimer

Applicant submits herewith a terminal disclaimer to U.S. Patent No. 7,514,078.

CONCLUSION

Applicant respectfully submits that all pending claims are in condition for allowance and

request early favorable action. If the Examiner believes a telephonic interview would expedite the prosecution of the application, the Examiner is welcome to contact Applicant's Agent at the

number below.

Date: September 24, 2009

Tel. No.: (617) 526-9893 Fax No.: (617) 526-9899 Agent for the Applicant Proskauer Rose LLP One International Place

Isaac A. Hubner, Reg. No. 61,393

Respectfully submitted

Boston, MA 02110